Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 2/20 | 0.43 |
| ▸ | PDE9A | O76083 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630342 | 1.00 | HSP90AA1 (1.00) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL29598579 | 1.00 | HSP90AA1 (1.00) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL5632986 | 0.91 | HSP90AA1 (0.83) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL29948904 | 0.91 | HSP90AA1 (0.83) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL29748943 | 0.91 | HSP90AA1 (0.83) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL3102522 | 0.91 | HSP90AA1 (0.83) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL12288836 | 0.91 | HSP90AA1 (0.83) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL9118693 | 0.89 | HSP90AA1 (0.81) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL2564507 | 0.89 | HSP90AA1 (0.81) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL5132212 | 0.88 | HSP90AA1 (0.78) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149717-A1 | METHODS AND COMPOSITIONS RELATED TO DOPAMINERGIC NEURONAL CELLS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2013-06-13 | — | — | US | claimed |
| US-20070148185-A1 | Novel therapeutic target for protozoal diseases | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | 2007-06-28 | — | — | US | claimed |
| US-7211561-B2 | Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa) | CEDARS-SINAI MEDICAL CENTER (US) | 2007-05-01 | — | — | US | claimed |
| US-20070032471-A1 | Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | claimed |
| EP-1651204-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A 2,5-DIHYDROXYBENZENESULFONIC COMPOUND AND A POTASSIUM ION CHANNEL MODULATOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-05-03 | — | — | EP | claimed |
| WO-2005013962-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A 2,5-DIHYDROXYBENZENESULFONIC COMPOUND AND A POTASSIUM ION CHANNEL MODULATOR | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-02-17 | — | — | WO | claimed |
| WO-2004056181-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (2) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| WO-2004056180-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (1) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| US-20030060487-A1 | Treatment of neurodegenerative disease | MINERVA BIOTECHNOLOGIES CORPORATION | 2003-03-27 | — | — | US | claimed |
| EP-0617023-B1 | Benzimidazole derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1998-10-21 | — | — | EP | claimed |
| US-5475015-A | Benzimidazole derivatives, their preparation and pharmaceutical use | NEUROSEARCH A/S (DK) | 1995-12-12 | — | — | US | claimed |
| EP-0617023-A1 | Benzimidazole derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1994-09-28 | — | — | EP | claimed |
| JP-6321910-A | — | — | None | — | — | JP | disclosed |
| US-12605367-B2 | Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies | Universite de Bordeaux (FR) | 2026-04-21 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| CN-110575453-B | Application of NS1619 in inhibiting NLRP3 inflammatory body activation | 中国科学技术大学 | 2023-04-21 | — | — | CN | disclosed |
| EP-0617023-B1 | Benzimidazole derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1998-10-21 | — | — | EP | disclosed |
| US-5475015-A | Benzimidazole derivatives, their preparation and pharmaceutical use | NEUROSEARCH A/S (DK) | 1995-12-12 | — | — | US | disclosed |
| JP-H06321910-A | BENZIMIDAZOLE DERIVATIVE, PREPARATION THEREOF AND USE THEREOF | NEUROSEARCH AS | 1994-11-22 | — | — | JP | disclosed |
| EP-0617023-A1 | Benzimidazole derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1994-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060487-A1 | Treatment of neurodegenerative disease | HTT, IAPP, APP | HSP90AA1 1150/4885MAPT 9/4885MEN1 2093/4885 |
| US-12605367-B2 | Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies | KCNN3, KCNN1, KCNN2 | HSP90AA1 3685/4885MAPT 1137/4885MEN1 1350/4885 |
| US-20070032471-A1 | Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator | KCNN2, KCNA5, KCNJ2 | HSP90AA1 1719/4885MAPT 3504/4885MEN1 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.